Aydın BALCI, Muhammed Emin DÜZ, Elif MENEKŞE

D-dimer seviyeleri ve COVID-19 şiddeti: Sistematik Derleme ve Metaanaliz

Giriş: Koronavirüs hastalığı 2019 (COVID-19), Aralık 2019’da Wuhan’da keşfedilen, çok sayıda asemptomatik vaka ve uzun bir kuluç-ka dönemi ile ölümcül ve pandemik bir hastalıktır. Araştırmacılar, yüksek D-dimer seviyelerinin hastalık şiddetini, akciğer komplikas-yonlarını ve tromboembolik olayları ortaya çıkmadan önce tahmin edebileceğini öne sürdü.Materyal ve Metod: PubMed, Scopus ve Web of Science’ta “D-dimer” ve “koronavirüs” veya “D-dimer” ve “COVID-19” anahtar kelimelerini kullanarak arama yaptık. Sürekli verilerin forest plot analizi ve COVID-19 enfeksiyonlu, şiddetli ve şiddetli olmayan has-talar arasındaki serum D-dimer konsantrasyonlarındaki farklılıkları değerlendirmek için Standart Ortalama Farklılıkları (SMD) kullan-dık. P değerini

D-dimer levels and COVID-19 severity: Systematic Review and Meta-Analysis

Introduction: Coronavirus disease 2019 (COVID-19) is a fatal and pandemic disease discovered in December 2019 in Wuhan, with lots of asymptomatic cases and a long incubation period. The researchers suggested that high d-dimer levels could predict disease severity, lung complications, and throm-boembolic events before they occur. Materials and Methods: We searched in PubMed, Scopus, and Web of Science using the keywords “D-dimer” and “coronavirus” or “D-dimer” and “COVID-19.” We used Standardized Mean Differences (SMD) to build forest plots of continuous data and assess differences in serum D-dimer concentra-tions between severe and non-severe patients with COVID-19 disease. We evaluated p-value < 0.05 as statistically significant and preferred 95% confi-dence intervals (CIs).Results: The pooled results of all studies revealed that the D-dimer concentra-tions were significantly higher in patients with more severe COVID-19 (SMD: 2.32 μg/mL; 95% CI, 0.72 3.92 μg/mL, p< 0.001). We evaluated severe pati-ents with total D-dimer levels. D-dimer concentrations were significantly hig-her in severe patients against total COVID-19 patients (SMD: 2.01 μg/mL; 95% CI, 0.25 to 3.77 μg/mL, p= 0.08).Conclusion: We do not know the D-dimer increment mechanism in severe patients yet, but we think that these findings will be useful in the early diag-nosis of severe disease and the first treatment.

PDF

___

1. ArcGIS. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Johns Hopkins University. Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/ index.html#/bda7594740fd40299423467b48e9ecf6 Accessed date: 27 Sept 2020.
2. Du Toit A. Outbreak of a novel coronavirus. Nat Rev Microbiol 2020; 18: 123.
3. European Centre for Disease Prevention and Control. Q & A on COVID-19: Basic facts. Available from: https://www. ecdc.europa.eu/en/covid-19/facts/questions-answersbasic- facts Accessed date: 18 Sept 2020.
4. Liu B, Li M, Zhou Z, Guan X, Xiang YJ. Can we use the interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Autoimmun 2020; 111: 102452.
5. Dolhnikoff M, Duarte-Neto AN, de AlmeidaMonteiro RA, Ferraz da Silva LF, Pierre de Oliveira E, Nascimento Saldiva PH, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost 2020; 18: 1517-9.
6. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and prospects. Blood 2009; 113(13): 2878- 87.
7. Lippi G, Favaloro EJ. D-dimer is associated with the severity of coronavirus disease 2019: A pooled analysis. Thromb Haemost 2020; 120: 876-8.
8. Mouat B, Besutti M, Bouiller K. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. Eur Respir J 2020; 56(4): 2001811.
9. Pizzi R, Gini G, Caiano L, Roveda A, Bertù L, Ageno W, et al. Coagulation parameters and venous thromboembolism in patients with and without COVID-19 admitted to the emergency department for acute respiratory insufficiency. Thromb Res 2020; 196: 209-12.
10. Santotoribio JD, Nuñez-Jurado D, Lepe-Balsalobre E. Evaluation of routine blood tests for diagnosis of suspected coronavirus disease 2019. Clin Lab 2020; 66(9): 200522.
11. Cheng A, Hu L, Wang Y, Huang L, Zhao L, Zhang C, et al. Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. Int J Antimicrob Agents 2020; 56(3): 106110.
12. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D‐dimer levels on admission to predict in‐hospital mortality in patients with COVID‐19. J Thromb Haemost 2020; 18: 1324-9.
13. Fu J, Kong J, Wang W, Wu M, Yao L, Wang Z, et al. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. Thromb Res 2020; 192: 3-8.
14. Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Nigoghossian CD, et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and ımplications for future research. Thromb Haemost 2020; 120(7): 1004-24.
15. Ye W, Chen G, Li X, Lan X, Ji C, Hou M, et al. Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19. Respir Res 2020; 21(1): 169.
16. Yu B, Li X, Chen J, Quyang M, Zhang H, Zhao X, et al. Evaluation of variation in D-dimer levels among COVID- 19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis 2020; 50(3): 548-57.
17. Li C, Hu B, Zhang Z, Qin W, Zhu Z, Zhai Z, et al. D‐dimer triage for COVID‐19. Academic Emergency Medicine 2020; 27: 612-3.
18. Li Y, Zhao K, Wei H, Chen W, Wang W, Jia L, et al. Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol 2020; 190(1): e24-e7.
19. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case-control study. J Intensive Care 2020; 8: 49.
20. Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad. Clin Rheumatol 2020; 39(9): 2529-43.
21. Kutny MA, Rajpurkar M, Alonzo TA, Gerbing RB, Games AS, Feusner JH, et al. Evaluation of ISTH DIC score to predict significant bleeding and thrombosis events in pediatric acute promyelocytic leukemia; a report from the children’s oncology group AAML0631 trial. Blood 2014; 124 (21): 3669.
22. American Society of Hematology. Lee AYY, Connors JM, Baumann Kreuziger L, Murphy M, Gernsheimer T, Yulia Lin, et al. COVID-19 and Coagulopathy: Frequently Asked Questions. Available from: https://www.hematology.org/ covid-19/covid-19-and-coagulopathy